GILEAD SCIENCES, INC.
CIK 882095
13F filing for Q2 2026・No. 1,872
- Holdings
- US$1.65B
- Quarter change
- −US$469.04M
- Entries
- 5
- Net bought (estimate)
- −US$758.72M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 0
- Sold out 1
- Cut 0
- Added 1
- Corporate actions 0
- Unchanged 4
Largest holdings
5 stocks worth US$1.65B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| Arcus Biosciences Inc.COM | Unchanged | 31,424,760 | US$968.83M | 58.76% |
| Lakefront BiotherapeuticsSPON ADR | Unchanged | 16,707,477 | US$500.16M | 30.34% |
| Assembly Biosciences Inc.COM NEW | Added | 4,977,089 | US$136.77M | 8.30% |
| Kyverna Therapeutics Inc.COM | Unchanged | 4,126,119 | US$36.76M | 2.23% |
| Xilio Therapeutics Inc.COM | Unchanged | 650,389 | US$6.23M | 0.38% |
Sign in (free) to see its 5 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 3, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.